Catalyst Dossier · compiled by CeliA 🧫

Insmed Incorporated (INSM)

Pharmaceutical Preparations · market cap $20.8B · as of 2026-06-25

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Insmed Incorporated (INSM) is a specialty pharmaceutical company with 1,271 employees and a ~$22.1B market cap, focused primarily on rare and serious pulmonary diseases. Its most advanced commercial-stage asset is Arikayce (liposomal amikacin for inhalation), with a broad pipeline spanning NTM lung disease, non-cystic fibrosis bronchiectasis (brensocatib), pulmonary hypertension (treprostinil palmitil inhalation powder), and several other indications. The highest-impact near-term catalyst is a Phase 3 readout for treprostinil palmitil in pulmonary hypertension expected by end of 2026.

The catalyst path

2026-08-06Earningsimp 5/10
2026-12-31 (est.)Phase 3 · Treprostinil Palmitilimp 9/10

Pipeline

Asset	Phase	Indication
280 mg Arikayce™	Phase 2	Bronchiectasis
Liposomal amikacin for inhalation	Phase 3	Cystic Fibrosis
LAI 590 mg	Phase 3	NTM Lung Infection Due to MAC
Cisplatin liposomal	Phase 2	Osteosarcoma Metastatic
Brensocatib 25 mg	Phase 3	Non-Cystic Fibrosis Bronchiectasis
Arikayce™ 560 mg	Phase 2	Cystic Fibrosis
Mometasone furoate nasal spray (MFNS)	Phase 2	Chronic Rhinosinusitis Without Nasal Polyps
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.	Phase 3	Pseudomonas Aeruginosa Infection
Treprostinil Palmitil Inhalation Powder	Phase 3	Pulmonary Hypertension
ARIKACE™	Phase 2	Cystic Fibrosis
Liposomal amikacin for inhalation (LAI)	Phase 2	Mycobacterium Infections, Nontuberculous
Brensocatib	Phase 2	Hidradenitis Suppurativa
Treprostinil Palmitil	Phase 3	Pulmonary Hypertension
Arikayce™	Phase 2	Cystic Fibrosis
ALIS	Phase 3	Mycobacterium Infections, Nontuberculous
Azithromycin	Phase 3	Mycobacterium Infections, Nontuberculous
LAI (Liposomal Amikacin for Inhalation) 590 mg	Phase 3	Mycobacterium Infections, Nontuberculous
Brensocatib 10 mg	Phase 3	Non-Cystic Fibrosis Bronchiectasis
rhIGF-I/rhIGFBP-3	Phase 3	Myotonic Dystrophy Type 1

Price & technical context

3-month

-34.6%

6-month

-39.3%

12-month

+8.9%

52-wk range

$91.88–$211.41

vs 50-day MA

-4.5%

vs 200-day MA

-29.7%

Realized vol

55.3%

Max drawdown

-56.5%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for INSM (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 19 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.